The effect of a heparin removal filter on platelet aggregation studies in heparin-induced thrombocytopenia

J F Caple1, K Kottke-Marchant, M L Miller

  • 1Cleveland Clinic Foundation, Ohio 44195, USA.

Patients having a heparin-associated platelet antibody who are receiving heparin at the time of testing for heparin-induced thrombocytopenia (HIT) by platelet aggregometry may exhibit aggregation in the negative control channel. Filtering plasma to remove the heparin in may produce a nonaggregating negative control channel. The effect of the Pall Hepchek (Pall Biomedical, East Hills, NY) heparin removal filter on platelet aggregation studies was evaluated. Samples were studied from 10 patients with clinically established HIT. The pre-filtration platelet aggregation studies were unequivocally positive for heparin antibody. The remainder of each sample was filtered and the aggregation studies were repeated. Of the four patients on IV heparin, only one remained positive post-filtration. Of the six patients receiving subcutaneous heparin or flushes, one remained strongly positive, one was borderline, and four became negative. Pall Hepchek heparin filtration unpredictably alters the results of platelet aggregation studies, and should not be used routinely to remove heparin in the presence of aggregation in the negative control.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
114
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
843